OutPerformDaily

  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks

Lost Password?

Top 3 AI Stocks to Invest in Right Now

Fake shopping sprees and ‘happiness insurance’: The latest fintech apps reveal our financial anxieties

Is Apple’s foldable iPhone Duo worth $2,000? See how it stacks up against other foldable phones.

I gave my HomeExchange guest a 5-star review. Then I found heat marks all over my dining table. Do I call her out?

Inside the push to weaken Washington’s toughest financial watchdog

Scared to spend your retirement money? Here’s one way to get over the fear of running out.

OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
OutPerformDaily
  • Tech Stocks
  • Cannabis Stocks
  • Index Funds
  • International
  • Short
  • Stock Picks
3rdPartyFeeds

Shares of GE Vernova slide as investors focus on the wrong part of its business

January 28, 2026

Our focus is on the continued robust results from the power and electrification businesses, where demand is off the charts. Read more...

3rdPartyFeeds

Corning’s Meta deal and earnings tell us this stock is nowhere near done going up

January 28, 2026

As strong as Corning's quarterly results were, profit-takers were understandably stepping in. Read more...

3rdPartyFeeds

Danaher stock fails to rise on solid earnings — leading us to question what’s next

January 28, 2026

While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like. Read more...

3rdPartyFeeds

Starbucks CEO Brian Niccol ‘cracked the code’ as the brand’s revival gains ground

January 28, 2026

It's the first time in 2 years that Starbucks has seen an increase in U.S. comparable transactions. Read more...

Bleeding Disorders Treatment Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Takeda Pharmaceutical Co., Roche, Novo Nordisk, Pfizer, Bayer and More
Uncategorized

Bleeding Disorders Treatment Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Takeda Pharmaceutical Co., Roche, Novo Nordisk, Pfizer, Bayer and More

January 28, 2026

The bleeding disorders treatment market is expanding due to increased diagnosis rates and government support, with significant growth driven by gene therapies...

3rdPartyFeeds

Here’s a look at 4 portfolio stock earnings and our takeaways on each

January 28, 2026

We're busy working away on the four earnings reports from portfolio companies Wednesday morning. Read more...

3rdPartyFeeds

Starbucks stock jumps as coffee chain’s traffic grows for the first time in two years

January 28, 2026

Shares of Starbucks have fallen more than 3% over the last year. Read more...

Amazon cuts 16,000 jobs globally to undo pandemic-era hiring
Uncategorized

Amazon cuts 16,000 jobs globally to undo pandemic-era hiring

January 28, 2026

Amazon announced a second major round of layoffs at the company in three months.

3rdPartyFeeds

SK Hynix pops 5% as it doubles profit in 2025 driven by the AI memory shortage

January 28, 2026

South Korea's SK Hynix on Wednesday posted record quarterly revenue and profit, to beat estimates. Read more...

3rdPartyFeeds

LVMH shares plummet 7% as fourth-quarter results lag competitors

January 28, 2026

LVMH shares plummeted Wednesday after the French luxury conglomerate reported mixed full-year earnings late Tuesday. Read more...

Previous 1 … 41 42 43 44 45 … 8,455 Next
Indices by TradingView

Categories

  • 3rdPartyFeeds
  • Cannabis Stocks
  • Index Funds
  • International
  • News
  • Short
  • Stock Picks
  • Tech Stocks
  • Uncategorized
Indices by TradingView
While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.